DOXYCHEL HYCLATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOXYCHEL HYCLATE (DOXYCHEL HYCLATE).
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA binding to the mRNA-ribosome complex.
| Metabolism | Partially metabolized in the liver via non-enzymatic pathways; primarily excreted unchanged in urine and feces. |
| Excretion | Doxycycline hyclate is primarily excreted via the feces (approximately 90%) as an inactive chelated complex, with renal excretion accounting for about 10% of the dose. Biliary excretion is minimal. |
| Half-life | Terminal elimination half-life is 18–22 hours in patients with normal renal function; prolonged to 20–30 hours in severe renal impairment. Clinical context: Allows once- or twice-daily dosing. |
| Protein binding | 90–93% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.75 L/kg (range 0.5–1.0 L/kg), indicating extensive tissue penetration and distribution into body fluids (e.g., pleural, ascitic, synovial). |
| Bioavailability | Oral: 90% (fasting); reduced by 20% with food or dairy. IV: 100%. |
| Onset of Action | Intravenous: Within 1 hour. Oral: 2–4 hours. Topical (gel/cream): 1–2 weeks for clinical improvement in acne. |
| Duration of Action | Duration of action is 24 hours following oral administration due to long half-life, supporting once-daily dosing. For acne, clinical improvement is noted after 2–4 weeks of topical use. |
100 mg orally or IV every 12 hours on day 1, then 100 mg daily.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR >10 mL/min; for GFR <10 mL/min, use with caution and consider dose reduction to 100 mg every 24 hours. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) and consider dose reduction. |
| Pediatric use | 8 years or older: 2.2 mg/kg every 12 hours on day 1, then 2.2 mg/kg daily; maximum 100 mg/dose. Not recommended under 8 years. |
| Geriatric use | Use with caution due to increased risk of esophageal irritation; consider starting at lower dose (e.g., 100 mg daily) and monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DOXYCHEL HYCLATE (DOXYCHEL HYCLATE).
| Breastfeeding | Doxycycline is excreted into breast milk in low concentrations (estimated M/P ratio: 0.5-0.8). Theoretical risk of dental staining and bone growth inhibition in nursing infants, but clinical significance is low due to limited gastrointestinal absorption. Caution recommended; alternatives preferred. |
| Teratogenic Risk | FDA Category D. First trimester: Avoid due to risk of fetal skeletal malformations and neural tube defects. Second/third trimester: Risk of permanent tooth discoloration (yellow-gray-brown) and hypoplasia of enamel; reversible inhibition of bone growth. Contraindicated after 4th month of gestation. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to doxycycline or any component","Children <8 years of age (except for specific indications like anthrax)","Pregnancy (absolute contraindication in second and third trimesters; caution in first)","Lactation (relative contraindication; use alternative if possible)","Severe hepatic impairment"]
| Precautions | ["Esophageal ulceration risk; take with adequate fluids","Photosensitivity reactions","Hepatotoxicity, especially in pregnancy or with pre-existing liver disease","Tooth discoloration and enamel hypoplasia in children <8 years","Skeletal development impairment in premature infants","Overgrowth of non-susceptible organisms including Clostridioides difficile","Intracranial hypertension (pseudotumor cerebri)","Antianabolic effect leading to increased BUN","Avoid in penicillin-allergic patients with severe allergy (not contraindicated but caution)","Exacerbation of systemic lupus erythematosus"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal liver function tests and renal function. Assess fetal growth and skeletal development via ultrasound if exposure occurs. In case of accidental use, dental follow-up for infant after tooth eruption. |
| Fertility Effects | No significant effect on fertility reported in human studies. Animal studies show no impairment. Doxycycline may transiently alter vaginal flora but does not impair gametogenesis. |